Income Statement (TTM)
Syndax Pharmaceuticals, Inc. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000,000 except per share units.
|
2020 09-30 |
2020 12-31 |
2021 03-31 |
2021 06-30 |
2021 09-30 |
2021 12-31 |
2022 03-31 |
2022 06-30 |
2022 09-30 |
2024 06-30 |
2024 09-30 |
2024 12-31 |
2025 03-31 |
2025 06-30 |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2 | 2 | 2 | 2 | 14 | 140 | 139 | 139 | 127 | 4 | 16 | 24 | 44 | 78 |
| Change (%) | 0.00 | 0.00 | 0.00 | 790.71 | 933.96 | -0.27 | -0.27 | -8.91 | -97.23 | 357.14 | 48.00 | 84.64 | 78.25 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| Cost Of Sales | 199 | 68 | 242 | 243 | 263 | |||||||||
| Change (%) | -65.78 | 255.47 | 0.36 | 8.22 | ||||||||||
| % of Revenue | 5,696.00 | 426.32 | 1,023.96 | 556.60 | 337.92 | |||||||||
| Gross Operating Profit | 2 | 2 | 2 | 2 | 14 | 140 | 139 | 139 | 127 | -196 | -52 | -219 | -200 | -185 |
| Change (%) | 0.00 | 0.00 | 0.00 | 790.71 | 933.96 | -0.27 | -0.27 | -8.91 | -254.74 | -73.34 | 319.05 | -8.76 | -7.12 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | -5,596.00 | -326.32 | -923.96 | -456.60 | -237.92 |
| SG&A | 23 | 23 | 22 | 22 | 23 | 25 | 26 | 29 | 30 | 92 | 106 | 121 | 139 | 154 |
| Change (%) | -1.59 | -1.09 | -0.92 | 4.43 | 9.59 | 4.61 | 8.14 | 5.04 | 207.17 | 15.02 | 14.07 | 14.90 | 10.62 | |
| % of Revenue | 1,507.51 | 1,483.52 | 1,467.37 | 1,453.86 | 170.46 | 18.07 | 18.95 | 20.55 | 23.70 | 2,632.29 | 662.30 | 510.47 | 317.66 | 197.13 |
| R&D | 44 | 50 | 63 | 69 | 80 | 88 | 96 | 109 | 111 | 163 | 5 | |||
| Change (%) | 13.55 | 24.40 | 9.45 | 16.31 | 10.49 | 9.24 | 13.34 | 1.19 | ||||||
| % of Revenue | 2,927.82 | 3,324.65 | 4,135.99 | 4,526.83 | 591.10 | 63.17 | 69.19 | 78.63 | 87.35 | 1,018.95 | 11.77 | |||
| OpEx | 67 | 73 | 85 | 91 | 103 | 113 | 123 | 138 | 141 | 291 | 337 | 363 | 387 | 417 |
| Change (%) | 8.41 | 16.54 | 6.73 | 13.42 | 10.29 | 8.21 | 12.22 | 1.98 | 107.39 | 15.69 | 7.75 | 6.62 | 7.64 | |
| % of Revenue | 4,435.33 | 4,808.17 | 5,603.36 | 5,980.69 | 761.56 | 81.23 | 88.14 | 99.18 | 111.04 | 8,328.29 | 2,107.57 | 1,534.43 | 886.03 | 535.06 |
| Operating Income | -66 | -71 | -83 | -89 | -89 | 26 | 17 | 1 | -14 | -288 | -321 | -340 | -344 | -339 |
| Change (%) | 8.60 | 16.89 | 6.86 | 0.20 | -129.33 | -36.98 | -93.14 | -1,332.36 | 1,960.75 | 11.54 | 5.75 | 1.18 | -1.34 | |
| % of Revenue | -4,335.33 | -4,708.17 | -5,503.36 | -5,880.69 | -661.56 | 18.77 | 11.86 | 0.82 | -11.04 | -8,228.29 | -2,007.58 | -1,434.43 | -786.03 | -435.06 |
| Interest Expense | -2 | -2 | -3 | -3 | -3 | -2 | -2 | -2 | -3 | -0 | -0 | -5 | -13 | -21 |
| Change (%) | 36.88 | 7.38 | -0.12 | 0.51 | -25.27 | 1.47 | 3.11 | 55.36 | -92.45 | -20.17 | 2,550.00 | 162.22 | 60.45 | |
| % of Revenue | -113.51 | -155.37 | -166.84 | -166.64 | -18.81 | -1.36 | -1.38 | -1.43 | -2.44 | -6.66 | -1.16 | -20.82 | -29.56 | -26.61 |
| Net Income | -67 | -73 | -86 | -91 | -92 | 25 | 15 | 1 | -14 | -264 | -297 | -319 | -331 | -335 |
| Change (%) | 9.62 | 17.07 | 6.83 | 0.22 | -127.18 | -37.90 | -94.72 | -1,804.89 | 1,793.60 | 12.49 | 7.30 | 3.90 | 1.14 | |
| % of Revenue | -4,399.14 | -4,822.54 | -5,645.68 | -6,031.18 | -678.62 | 17.84 | 11.11 | 0.59 | -11.02 | -7,545.20 | -1,856.64 | -1,346.11 | -757.52 | -429.84 |
Source: Capital IQ
